<DOC>
	<DOCNO>NCT02910557</DOCNO>
	<brief_summary>A Postmarketing Prospective Cohort Study Melanoma Patients Treated With IMLYGIC® ( Talimogene Laherparepvec ) Clinical Practice Characterize Risk Herpetic Infection Among Patients , Close Contacts , Health Care Providers ; Long-term Safety Treated Patients</brief_summary>
	<brief_title>Postmarketing Prospective Study Melanoma Patients Treated With IMLYGIC® Characterize Risk Herpetic Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patient provide write informed consent Patient adult ( ≥ 18 year age time informed consent ) diagnosis melanoma Patient enrol within 1 month receive first dose IMLYGIC treatment melanoma Patient prior history subject interventional clinical trial IMLYGIC</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>CTCAE - Common Terminology Criteria Adverse Events</keyword>
	<keyword>eCRF - electronic case report form</keyword>
	<keyword>ECOG - Eastern Cooperative Oncology Group</keyword>
	<keyword>EDC - electronic data capture</keyword>
	<keyword>GM-CSF - human granulocyte macrophage colony-stimulating factor</keyword>
	<keyword>HCP - health care provider</keyword>
	<keyword>HSV-1 - herpes simplex virus type 1</keyword>
	<keyword>ICF - informed consent form</keyword>
	<keyword>ICP - infect cell protein</keyword>
	<keyword>IEC - Independent Ethics Committee</keyword>
	<keyword>IRB - Institutional Review Board</keyword>
	<keyword>MedDRA - Medical Dictionary Regulatory Activities</keyword>
	<keyword>PFU - plaque-forming unit</keyword>
	<keyword>qPCR - quantitative polymerase chain reaction</keyword>
	<keyword>SmPC - Summary Product Characteristics</keyword>
	<keyword>USPI - United States Prescribing Information</keyword>
</DOC>